NR1H4 and metabolic dysfunction-associated steatotic liver disease: Obeticholic acid (OCA, 6α-ethylchenodeoxycholic acid, 1, Fig. 1) is a semisynthetic steroidal FXR agonist, which has validated FXR as a therapeutic target for NAFLD and NASH in clinical trials5,6.